Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
11 papers
Recent·Most cited
A. Malinova, D. Schreyer, E. Fiorini, D. Pasini, M. Bevere, S. D'Agosto, S. Andreani, F. Lupo, L. Veghini, S. Grimaldi, S. Pedron, C. Nourse, R. Salvia, G. Malleo, A. Ruzzenente, , V. Corbo
bioRxiv · Sep 27, 2023Cancer Biology
J. Xu, J. S. Roe, E. Lee, C. Tonelli, T. Somerville, M. Yao, J. Milazzo, H. Tiriac, A. Kolarzyk, E. Lee, J. Grem, A. Lazenby, J. Grunkemeyer, M. Hollingsworth, A. D. Borowsky, , C.-i. Hwang
This study shows EN1 promotes pancreatic cancer metastasis by repressing target genes and enhancing mesenchymal properties.
bioRxiv · Apr 10, 2023 · PreprintCancer Biology
M. Yao, J. Preall, J. Yeh, D. Pappin, P. Cifani, Y. Zhao, S. Shen, P. Moresco, B. He, H. Patel, A. Habowski, D. King, K. Raphael, A. Rishi, D. Sejpal, , D. Fearon
The paper identifies auto-antibodies secreted by plasma cells in PDAC against self-antigens, suggesting a link between chronic inflammation and autoimmunity.
bioRxiv · Mar 20, 2023 · PreprintCancer Biology
F. Lupo, F. Pezzini, E. Fiorini, A. Adamo, L. Veghini, M. Bevere, C. Frusteri, P. Delfino, S. D'Agosto, S. Andreani, G. Piro, A. Malinova, F. De Sanctis, D. Pasini, R. T. Lawlor, , V. Corbo
This study shows SEMA3A promotes aggressive basal-like PDAC by enhancing metastasis and modulating the tumor microenvironment through macrophage polarization and T cell exclusion.
bioRxiv · Feb 25, 2023Cancer Biology
C. Tonelli, G. N. Yordanov, Y. Hao, A. Deschenes, O. Klingbeil, H.-C. Ting, E. Brosnan, A. Doshi, Y. Park, C. R. Vakoc, J. Preall, D. Tuveson
The paper identifies SPDEF as a key driver of the classical subtype of pancreatic ductal adenocarcinoma, showing its role in tumor progression and dependence on specific target genes.
bioRxiv · Mar 18, 2022 · PreprintCancer Biology
L. Shaashua, M. Pevsner-Fischer, G. Friedman, O. Levi-Galibov, S. Nandakumar, R. Nevo, L. E. Brown, W. Zhang, Y. Stein, H. S. Kim, L. Bojmar, W. R. Jarnagin, N. Lecomte, R. Stok, H. Bishara, , R. Scherz-Shouval
This study shows BRCA mutations in pancreatic cancer alter CAF subtypes, specifically increasing CLU+ CAFs, and links this to HSF1 signaling.
bioRxiv · Aug 18, 2021 · PreprintCancer Biology
S. Bhatia, M. Kramer, S. Russo, P. Naik, G. Arun, K. Brophy, P. A. Andrews, C. Fan, C. M. Perou, J. Preall, T. Ha, D. Plenker, D. Tuveson, A. Rishi, J. E. Wilkinson, , D. L. Spector
This study develops and characterizes patient-derived TNBC organoids that recapitulate tumor properties and identify key signaling pathways involved in cancer progression.
bioRxiv · Aug 9, 2021Cancer Biology
P. Laise, M. Turunen, A. Curiel Garcia, L. Tomassoni, C. Maurer, E. Elyada, B. Schmierer, J. Worley, J. Kesner, X. Tan, E. Calvo Fernandez, K. Wong, U. Wasko, S. Tagore, A. L. E. Wang, , A. Califano
The paper identifies three developmental lineages in pancreatic cancer driven by master regulators and shows their association with MAPK activity and therapeutic vulnerabilities.
bioRxiv · Oct 27, 2020 · PreprintCancer Biology
E. Hasnis, H. Kim, S. Verma, Y. Feng, R. Almog, S. Matsliah, V. Vavinskaya, R. Alelbaum, O. Ben-Ishay, D. Tuveson, R. Sears, Z. A. Ronai
This study identifies RNF125's role in regulating HDAC2 and PDX1 to influence pancreatic cancer development and patient outcomes.
bioRxiv · Jan 6, 2020 · PreprintCancer Biology
T. Somerville, G. Biffi, J. Dassler-Plenker, K. Miyabayashi, Y. Xu, D. Maia-Silva, O. Klingbeil, O. Demerdash, M. Egeblad, D. Tuveson, C. Vakoc
This study shows that squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation by converting pancreatic stellate cells into inflammatory CAFs via TP63-dependent mechanisms.
bioRxiv · Nov 6, 2019Cancer Biology
V. Quaranta, C. Rainer, S. R. Nielsen, M. Raymant, M. S. Ahmed, D. Engle, A. Taylor, T. Murray, F. Campbell, D. Palmer, D. Tuveson, A. Mielgo, M. Schmid
This study shows that macrophage-derived granulin promotes resistance to immune checkpoint inhibitors in metastatic pancreatic cancer by excluding CD8+ T cells, and blocking granulin improves anti-tumor immunity.
bioRxiv · Dec 15, 2017Cancer Biology